HEALTH-RELATED QUALITY OF LIFE IN THE CARTITUDE-1 STUDY OFcilta-cel (GHS) in patients with relapsed/refractory multiple myeloma (RRMM)

Thomas Martin1, Yi Lin, Mouradz Agha, Adam D Cohen, Myo Htet, A Keith Stewart, Paramaswaran Hari, Jesus G Bardeau, Deepa Maddirala, Saad Z. Umerdarc, Yun Min Yeh, Alicia J Almendral, Yonel Olaya, Amor Banerjee, Jenna D Goldberg, Jordan M Schacht, Carolyn C Jackson, William Derr, Katherine S Gries, John Fastenau, Xiaoxi Xu, Marlene J Carrasco-Alfonso, Muhammad Aleem, Farah Hossain, Andrew Shabak, Sundar Jagannath

1UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; 2Memorial Sloan Kettering Cancer Center, New York, NY, USA; 3Immunocore, Cambridge, MA, USA; 4Institute for Cell and Molecular Biology, University of Texas at Austin, Austin, TX, USA; 5Institute for Immunology, University of Bonn, Bonn, Germany; 6Laboratory for Cell and Molecular Biology, University of Bonn, Bonn, Germany; 7US National Institutes of Health, Bethesda, MD, USA; 8Levine Cancer Institute-Atrium Health, Charlotte, NC, USA; 9Janssen R&D, Paris, NJ, USA; 10Janssen R&D, Brussels, Belgium; 11Legend Biotech, Inc, USA; 12Fachry, LLC, USA; 13University of Chicago, Chicago, IL, USA

Key Eligibility Criteria
- Progressive MM per International Myeloma Working Group criteria
- Eastern Cooperative Oncology Group performance status ≤1
- Measurable disease
- ≥3 prior therapies or double refractory
- Prior proteasome inhibitor, immunomodulatory drug, anti-CD38 therapy

RESULTS (CONT'D.)

Methods
- Retail and price
- Scales Assessed
- Global health status
- Fatigue
- Fatigue
- Physical functioning
- Emotional functioning
- Social functioning
- Pain
- EQ-5D-5L
- Physical functioning
- Emotional functioning
- VAS
- Visual Analog Scale

RESULTS

Table 1. Baseline Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Phase 2 (N=68)</th>
<th>Median Range (years)</th>
<th>n= 50</th>
<th>51</th>
<th>50</th>
<th>45</th>
<th>47</th>
<th>35</th>
<th>37</th>
<th>36</th>
<th>39</th>
<th>33</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male (%)</td>
<td></td>
<td>42 (6.4)</td>
<td>48.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prior therapies for MM</td>
<td></td>
<td>6 (3-19)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pentax drug treatment</td>
<td></td>
<td>59 (68.8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pentax drug treatment</td>
<td></td>
<td>52 (41.7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Questionnaire Completion Rates

<table>
<thead>
<tr>
<th>Questionnaire Completion Rates</th>
<th>EORTC CLQ-C30</th>
<th>EORTC CLQ-MY20 (4 Items)</th>
<th>EQ-5D-5L VAS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expected N (%)</td>
<td>Expected N (%)</td>
<td>Expected N (%)</td>
<td>Expected N (%)</td>
</tr>
<tr>
<td>Baseline 68</td>
<td>63 (92.6)</td>
<td>63 (92.6)</td>
<td>63 (92.6)</td>
</tr>
<tr>
<td>Day 100 65</td>
<td>54 (83.1)</td>
<td>53 (81.5)</td>
<td>54 (83.1)</td>
</tr>
<tr>
<td>Day 212 53</td>
<td>36 (67.9)</td>
<td>36 (67.9)</td>
<td>36 (67.9)</td>
</tr>
</tbody>
</table>

Figure 3. Improvement in Physical Functioning and GHS Over Time

Figure 4. Improvement in Pain and Fatigue Over Time

Figure 5. Improvement in Overall HQRoL, Pain, and Fatigue at Day 100 Post Infusion by Treatment Response

CONCLUSIONS
- Patients with heavily pretreated MM showed rapid and clinically meaningful improvements in HRQoL after cilta-cel infusion.
- Improvements in pain, fatigue, physical functioning, general health status, and disease-related health status were consistent with their clinical outcomes.
- Trend for HROG improvements with increased depth of response suggest further HROG benefits could be expected as responses may deepen over time with cilta-cel.
- Limitations
- Patient-reported outcomes were based on a relatively small sample size.
- The results presented are exploratory and descriptive summary of patient’s self-reported outcomes.

REFERENCES

https://comylive.cme-congresses.com/